Verpackung (Glas/Pouchbag)
A method of reversing, ameliroating or slowing progression of at least one symptom of Parkinson's disease in a patient in need thereof, comprising the step of administering to said patient an amount of one or more hepatocyte growth factor mimics sufficient to reverse, ameliorate or slow progression of said at least one symptom of Parkinson's disease, said one or more hepatocyte growth factor mimics having a general structural formula 1 2 3 wherein Ri is one of an N-acyl group, a substituted or unsubstituted phenyl, a norleucine group, and an amino acid selected from tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine norvaline, ornithine, and s-benzyl cysteine
IGF-1 LR3 Reconstitution Reference (0.1 mg / 100 mcg vial) BAC water added 0.5 mL Concentration 200 mcg/mL 20 mcg dose 0.10 mL (10 units) 40 mcg dose 0.20 mL (20 units) 50 mcg dose 0.25 mL (25 units) BAC water added 1 mL Concentration 100 mcg/mL 20 mcg dose 0.20 mL (20 units) 40 mcg dose 0.40 mL (40 units) 50 mcg dose 0.50 mL (50 units) Smaller vials are typically used for short cycles or first-cycle assessment
TGF-beta pathway activation organizes the actin cytoskeleton in fibroblasts, restoring collagen contraction and remodeling capacity
